Plasma concentrations of morphine,morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain

Abstract

Morphine, the recommended drug for the management of moderate to severe cancer pain, is metabolized predominantly to the glucuronides morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). The quantitative clinical importance of these metabolites following the administration of oral morphine is unclear. This study investigates the relationship between plasma concentrations of morphine (M), M6G, M3G and clinical effects in patients receiving sustained release oral morphine for cancer-related pain.

Peak and trough plasma concentrations of morphine and its metabolites were determined by high-performance liquid chromatography (HPLC). At corresponding time points, pain [Visual Analogue Scales (VAS), Verbal Rating Scales (VRS), Pain Relief Scores (PRS)] and toxicity (VAS and VRS) were assessed. Renal and liver function tests were performed.

Forty-six patients were included in the study. There was a significant correlation between dose and both peak and trough plasma M, M6G and M3G (r>0.60, P<0.001 for each). Differences between peak and trough M, M6G, M3G, M / M6G, M6G:M, M3G:M and M3G:M6G were all significant (P<0.001 for each). Pain was generally well controlled in the group, with a median VAS of 15 mm at the peak blood sampling time point. The differences between peak and trough values for VAS pain, VAS nausea and VAS drowsiness were not statistically significant (P = 0.078, 0.45 and 0.099, respectively).

There were no differences in peak or trough morphine and metabolite concentrations or ratios between patients with low (< median) or high pain scores. Similarly, there was no significant relationship between high and low plasma concentrations and clinical effect.

This study did not identify a simple relationship between plasma concentrations of morphine, morphine metabolites or metabolite ratios and clinical effects in patients with cancer and pain who were receiving chronic oral morphine therapy. Although overall pain control was good, there was marked interpatient variability in the dose of morphine and the plasma concentrations necessary to achieve this degree of analgesia.

Keywords

cancer pain morphine morphine-3-glucuronide morphine-6-glucuronide morphine metabolites

Get full access to this article

View all access options for this article.

References

World Health Organization . Cancer pain relief, second edition. Geneva: WHO, 1986.

McQuay H . Opioids in chronic pain. Br J A naesth 1989; 63: 213–226.

Boerner U , Abbott S , Roe S . The metabolism of morphine and heroin in man. Drug M etab Rev 1975; 4: 39–73.

Gong QL , Hedner J , Bjorkman R , et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249–255.

Hewett K , Dickenson A , McQuay H . Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 53: 59–63.

Penson RT , Joel SP , Bakhshi K , Clark SJ , Langford RM , Slevin ML . Randomised placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68: 667–676.

Hanna MH , Peat SJ , Woodham M , Knibb A , F ung C . Analgesic ef®cacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J A naesth 1990; 64: 547–550.

Osborne R , Thompson P , Joel S , Trew D , Patel N , Slevin M . The analgesic activity of morphine-6-glucuro nide. Br J Clin Pharmacol 1992; 34: 130–138.

Portenoy RK , Thaler HT , Inturrisi CE , Friedlander-Klar H , Foley KM . The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol T her 1992; 51: 422–431.

10.

Peat SJ , Hanna MH , Woodham M , et al. Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain 1991; 45: 101–104.

11.

Lotsch J , Kobal G , Geisslinger G . No contribution of morphine-6-glucu ronide to clinical morphine effects after short-term administration. Clin Neuropharmacol 1998; 21: 351–354.

12.

Penson R. Morphine analgesia in cancer pain: the role of the glucuronides. M D thesis, University of London, London, 1999.

13.

Faura CC , Moore RA , Horga JF , Hand CW , McQuay HJ . Morphine and morphine-6-glucu ronide plasma concentrations and effect in cancer pain. J Pain Symptom M anage 1996; 11: 95–102.

14.

Joel S , Osborne R , Slevin M . An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J Chromatogr 1988; 430: 394–399.

15.

McQuay HJ , Carroll D , Faura CC , Gavaghan DJ , Hand CW , Moore RA . Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236–244.

16.

Ashby M , Fleming B , Wood M , Somogyi A . Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom M anage 1997; 14: 157–167.

17.

McQuay H , Moore R . Opioid problems, and morphine metabolism and excretion. In: Dickenson A , Besson J eds. Experimental pharmacology, Volume 130. Berlin: Springer-Verlag, 1997: 335–360.

18.

Klepstad P , Kaasa S , Borchgrevink PC . Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000; 55: 713–719.

19.

Tiseo PJ , Thaler HT , Lapin J , Inturrisi CE , Portenoy RK , Foley KM . Morphine-6-glu curonide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47–54.

20.

Wolff T , Samuelsson H , Hedner T . Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995; 62: 147–154.